Pay in 4 interest-free payments of $18.75 Learn more
Ships within 48 hours · Estimated delivery Jul 29 - Aug 3
and the ex vivo synthesis of TXB2 and PGE2 in rats
SAR-20347 inhibits TYK2- and JAK1-mediated IL-12 and IFN-α signaling
OCCOCCN1CCN(CC1)C1=NC2=CC=CC=C2SC2=CC=CC=C21
Chemical Name: 4-(4-fluorophenyl)-N-[3-methoxy-4-(4-methyl-1H-imidazol-1-yl)phenyl]-4
semi-synthetic
Canagliflozin - CAS# 842133-18-0 Catalog No.:M10730-10 and the ex vivo synthesisCanagliflozin (INN, trade name Invokana) is a drug for the treatment of type 2 diabetes. It was developed by Mitsubishi Tanabe Pharma and is marketed under license by Janssen, a division of Johnson & Johnson. Canagliflozin is an inhibitor of subtype 2 sodium glucose transport protein (SGLT2), which is responsible for at least 90% of the glucose reabsorption in the kidney. Blocking this transporter causes blood glucose to be eliminated through the